News

Good news doesn’t cancel out the bad stuff
Enlarge image

BusinessSwitzerland

Good news doesn’t cancel out the bad stuff

17.04.2012 - Swiss Addex has announced positive results from ongoing studies.
Yet it is dismissing 28 workers – perhaps a delayed effect from bad news last fall.

Geneva – On April 16, only three days after the announcement that its ongoing restructuring efforts will result in laying off 28 employees, Swiss Addex Therapeutics reported positive preclinical data for its lead GABA-B receptor modulator. The orally administered small molecule ADX71441 is a positive allosteric modulator (PAM). In both guinea pig and mouse studies, the selective activation of GABA-B alleviated symptoms in disease-relevant models of  overactive bladder (OAB). While Addex aims for IND/CTA filing before the end of the year, another PAM is already being evaluated in a Phase 2a clinical trial by Addex’ partner Janssen Pharmaceuticals. Activating the glutamate receptor mGluR2 with ADX71449 is being tested to treat schizophrenia.

Yet even better news was publicised in March when Addex reported that in a Phase 2a clinical trial, all key objectives had been achieved: Parkinson’s disease patients suffering from levodopa-induced dyskinesia (LID) were given oral dipraglurant, a small molecule allosteric modulator selectively inhibiting the glutamate receptor mGluR5. The compound not only proved to be safe and tolerable but also significantly reduced dyskinesia severity. In terms of sentiment, however, this news doesn’t make up for the announced workforce cut required. President and CEO of Addex, Bharatt Chowrira, said: „We deeply regret the loss of people’s jobs at Addex but we believe it is necessary to improve the operational efficiency.“

Addex was forced to sail close to the wind last November when Merck & Co. opted not to continue the joint development of ADX88178, a PAM targeting mGluR4. The drug is also assigned to treat Parkinson’s disease. The current lay-offs could very well be the delayed effects of Merck leaving Addex high and dry. 

http://www.european-biotechnology-news.com/news/news/2012-02/good-news-doesnt-cancel-out-the-bad-stuff.html

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

M&AIrelandEU

07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • FORMYCON (D)24.56 EUR5.59%

FLOP

  • SERODUS (N)1.46 NOK-14.12%
  • PHOTOCURE (N)39.50 NOK-7.49%
  • BIONOR PHARMA (N)0.79 NOK-7.06%

TOP

  • AB SCIENCE (F)18.84 EUR71.3%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.17 EUR36.1%

FLOP

  • SERODUS (N)1.46 NOK-28.8%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)50.00 SEK-19.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.20 SEK2022.4%
  • NICOX (F)8.55 EUR352.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.10 SEK-88.0%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.69 EUR-76.5%

No liability assumed, Date: 30.04.2016